From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases
Malignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully...
Salvato in:
| Autori principali: | , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2024-04-01
|
| Serie: | Frontiers in Immunology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1276306/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
